Title of article :
Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer.
Author/Authors :
Basi، Ali نويسنده Assistant professor of Medical Oncology and Hematology, Iran University of Medical Sciences (IUMS), Tehran, Iran. Basi, Ali , Sohrabkhani، Shahab نويسنده Internist, Iran University of Medical Sciences (IUMS), Tehran, Iran. Sohrabkhani, Shahab , Zamani، Farhad نويسنده , , Baghai-Wadji، Masoud نويسنده Associated professor of Surgery, Iran University of Medical Sciences (IUMS), Tehran, Iran. Baghai-Wadji, Masoud , Rabiei، Neda نويسنده Resident of internal Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran. Rabiei, Neda , Razavi، Seyyed-Mohsen نويسنده Assistant professor of Medical Oncology and Hematology, Iran University of Medical Sciences (IUMS), Tehran, Iran. Razavi, Seyyed-Mohsen , ajdarkosh، hossein نويسنده tehran university of medical science ,
Issue Information :
فصلنامه با شماره پیاپی 0 سال 2013
Pages :
17
From page :
8
To page :
24
Abstract :
Background: Recent researches have led to find strategies to prevent relapse and to improve survival for gastric cancer patients, including preoperative neo-adjuvant approaches. However, the efficacy of some neo-adjuvant regimens including 5-fluorouracil, cisplatin, and docetaxel have been less investigated. The present study evaluated the outcome and mid-term survival of patients with gastric cancer who undergoing this regimen.
Methods: In a randomized double-blinded controlled trial performed at the Firoozgar hospital in Tehran in 2011-12, 61 patients were randomly assigned to treatment (32 to neo-adjuvant chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU) before surgery and 27 to surgery alone). The present study tried to assess the efficacy of neoadjuvant chemotherapy regarding improvement of mid-term survival, complications, and R0 resection status.
Results: The two groups were matched in terms of gender, mean age, cancer location, and TNM staging. However, R0 resection in the former group was 85.7%; while this indicator in the isolated surgery group was significantly lower (61.5%). Regarding WHO performance, no significant difference was observed across the two groups. Patients in neo-adjuvant chemotherapy group were followed for mean follow-up time 10.32 months and those who categorized in isolated surgery group were followed for mean follow-up time 10.88 months. Mid-term mortality rate in the two groups was 14.3% and 15.4%, respectively (p = 0.866). In this regard, 3-, 6-, and 9-month survival rate in neo-adjuvant chemotherapy group was 96.4%, 89.3%, and 85.7%, respectively. These survival rates in the surgery group were 92.3%, 88.5%, and 84.6%, respectively. Multivariable logistic regression analysis showed that among all study variables, only R0 resection status could predict mid-term mortality.
Conclusion: Neo-adjuvant chemotherapy and surgery compare to surgery alone more improve R0 resection status, but mid-term survival rate is similar in the two regiments. R0 resection status can effectively predict appropriate mid-term survival in undertreated patients.
Journal title :
International Journal of Hematology-Oncology and Stem Cell Research (IJHOSCR)
Serial Year :
2013
Journal title :
International Journal of Hematology-Oncology and Stem Cell Research (IJHOSCR)
Record number :
2393642
Link To Document :
بازگشت